Revance Names Nashville Its New Home

Revance Therapeutics is relocating to Nashville. In conjunction with Tennessee Gov. Bill Lee and Tennessee Department of Economic and Community Development (TNECD) Commissioner Bob Rolfe, the company says it is leaving its current home in Silicon Valley’s Newark, CA.

Revance will invest more than $10 million and create nearly 150 jobs over the next five years in addition to the company’s more than 450 employees currently located in its California offices and throughout the U.S.

The new headquarters will include a training and education center where employees, healthcare providers, consumers, and patients can learn about the latest innovations in the company’s aesthetics, therapeutics, and financial technology (fintech) products and services.

Revance Therapeutics’ daxibotulinumtoxinA for Injection is currently under review with the FDA for glabellar (frown) lines and is being evaluated in other aesthetics and therapeutic indications, including cervical dystonia and adult upper limb spasticity.

Revance this year launched a unique portfolio of premium products and services for aesthetics practices, including exclusive the RHA® Collection of dermal fillers, the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and HintMD, a fintech platform that offers integrated smart payment, subscription and loyalty services. 

“We are pleased to welcome another West Coast, California-based company to Tennessee. Revance Therapeutics is on the cutting edge of biotechnology and will be an asset to Nashville’s business landscape,” says Mr. Rolfe. We thank the company for choosing Tennessee for this project and for creating 150 new jobs in Davidson County.” 

“We are thrilled to be relocating our corporate headquarters to Nashville as the area will provide the foundation for our new, world-class training and education center and growth initiatives going forward. Nashville is one of the top business growth areas in the US offering an educated, diverse and growing population along with a favorable tax and policy environment for companies like ours, making it an ideal, centralized location for Revance’s future growth,” notes Mark J. Foley, president and CEO of Revance. “We anticipate our corporate relocation to be part of an increased investment in Nashville from other biotechnology and healthcare companies, as innovation and growth defines the city.”